JP6479475B2 - 薬剤投与量情報を決定するための方法及び装置 - Google Patents
薬剤投与量情報を決定するための方法及び装置 Download PDFInfo
- Publication number
- JP6479475B2 JP6479475B2 JP2014550529A JP2014550529A JP6479475B2 JP 6479475 B2 JP6479475 B2 JP 6479475B2 JP 2014550529 A JP2014550529 A JP 2014550529A JP 2014550529 A JP2014550529 A JP 2014550529A JP 6479475 B2 JP6479475 B2 JP 6479475B2
- Authority
- JP
- Japan
- Prior art keywords
- analyte
- processors
- user
- data
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 45
- 229940079593 drug Drugs 0.000 title description 6
- 239000003814 drug Substances 0.000 title description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 259
- 239000012491 analyte Substances 0.000 claims description 200
- 102000004877 Insulin Human genes 0.000 claims description 129
- 108090001061 Insulin Proteins 0.000 claims description 129
- 229940125396 insulin Drugs 0.000 claims description 129
- 230000008859 change Effects 0.000 claims description 54
- 230000015654 memory Effects 0.000 claims description 24
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 206010022489 Insulin Resistance Diseases 0.000 claims description 15
- 238000012937 correction Methods 0.000 claims description 15
- 210000003722 extracellular fluid Anatomy 0.000 claims description 9
- 230000035945 sensitivity Effects 0.000 claims description 8
- 230000007704 transition Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000012377 drug delivery Methods 0.000 claims description 2
- 238000005194 fractionation Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 2
- 238000012545 processing Methods 0.000 description 100
- 230000006854 communication Effects 0.000 description 63
- 238000004891 communication Methods 0.000 description 63
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 53
- 239000008103 glucose Substances 0.000 description 53
- 238000012544 monitoring process Methods 0.000 description 50
- 238000003860 storage Methods 0.000 description 12
- 238000012806 monitoring device Methods 0.000 description 11
- 230000006870 function Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000007726 management method Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 230000007175 bidirectional communication Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 229940127560 insulin pen Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 235000017848 Rubus fruticosus Nutrition 0.000 description 2
- 244000078534 Vaccinium myrtillus Species 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000021029 blackberry Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940107161 cholesterol Drugs 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- -1 etc.) Chemical compound 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000004382 potting Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
- A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1495—Calibrating or testing of in-vivo probes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Signal Processing (AREA)
- Artificial Intelligence (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Business, Economics & Management (AREA)
- Business, Economics & Management (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
・2mg/dL/分≦検体変化率 → 勧告投与量20%増、
・1mg/dL/分≦検体変化率<2mg/dL/分 → 勧告投与量10%増、
・−1mg/dL/分≦検体変化率<1mg/dL/分 → 勧告投与量無修正、
・−2mg/dL/分≦検体変化率<−1mg/dL/分 → 勧告投与量10%減、
・検体変化率≦−2mg/dL/分 → 勧告投与量20%減、
が適用される。
・(d/dt)g(t) = ((p1 + SI・X(t))g(t)) + (p1・Gb) - (p3・um(t)),
・(d/dt)X(t) = p2・(I(1) - Ib - X(t)),
・(d/dt)I(t) = -(p4・I) + ui(t),
と書かれる、「男性におけるブドウ糖許容量を制御する要因の生理学的評価、静脈内ブドウ糖に対する応答によるインスリン感受性及びベータ細胞ブドウ糖感受性の測定(Physiological Evaluation of Factors Controlling Glucose Tolerance in Man, Measurement of Insulin Sensitivity and Beta-cell Glucose Sensitivity from the Response to Intravenous Glucose)」,J, Clin, Invest.,The American Society for Clinical Investigation, Inc.,1981年12月,第68巻,p.1456〜1467に説明されている、バーグマンミニマルモデルの拡張である。ここで、ブドウ糖状態、有効インスリン状態及び血漿インスリン状態:g,X及びIは時間Iにかけて推定され、追跡される。時間が過ぎる内での食事及びインスリンの存在:um及びuiは系に対する未知の擾乱と見なされる。生理学的パラメータ:pl, pl, pJ, p4, SIは。また定常状態におけるブドウ糖値及びインスリン値:Gb及びIbも、以前の母集団データを用いて設定することができ、あるいは、設定し、次いで適切な適合アルゴリズムを用いて時間の経過にわたる適合を可能にすることができる。上記技術文献はその全体が本明細書に含められる。
・予測アラーム後の固定時点(例えば30分)、
・予測アラーム後のユーザ設定時点(例えば45分)、
・検体値が閾検体レベルを横切ったであろうという受信器デバイスの予測に基づく時点(例えば23分)、及び/または
・設定可能な予測アラームの所定の時間に等しい時点(例えば、10分、20分及び/または30分)、
にユーザに送られ得る。
101 センサ
102 データ処理ユニット(センサエレクトロニクス)
103 通信リンク
104 主受信器ユニット
105 データ処理端末
106 副受信器ユニット
110 一体化センサ/センサエレクトロニクスアセンブリ
210 皮膚表面
211 体表パッチ素子
220 読取器/受信器ユニット
222 ディスプレイ
240 信号
250 検体センサ
260 データ処理モジュール/端末
270 リモート端末
301 血糖検査ストリップインターフェース
302 RF受信器
303 入力
304 温度検出部
305 クロック
306 電源
307 処理/格納部
308 電力変換/監視部
309 受信器シリアル通信部
310 出力/ディスプレイ
Claims (18)
- 受信器ユニットにおいて実行される方法において、
生体内検体センサからユーザの検体レベルに関するデータを、1つ以上のプロセッサが受け取るステップ、
前記受け取られた検体データから前記ユーザの検体レベルを、前記1つ以上のプロセッサが決定するステップ、
前記受け取られた検体データ及び以前の検体データを用いて前記ユーザの前記検体レベルの変化率を、前記1つ以上のプロセッサが決定するステップ、
前記検体レベルの前記決定された変化率に対応する少なくとも1つのビンに前記ユーザの前記検体レベルに関する前記検体データを、前記1つ以上のプロセッサが分別するステップ、
前記ユーザの前記決定された検体レベルに基づいて、ボーラスである勧告インスリン投与量を、前記1つ以上のプロセッサが決定するステップ、
前記少なくとも1つのビンへの前記検体データの前記分別に基づいて、前記勧告インスリン投与量を、前記1つ以上のプロセッサが修正するステップ、並びに
間質液中検体レベルと血中検体レベルの間の時間差に基づいて前記勧告インスリン投与量を、前記1つ以上のプロセッサが修正するステップ、
を含むことを特徴とする方法。 - 前記勧告インスリン投与量及び前記修正勧告インスリン投与量の一方または両方を前記ユーザに、前記1つ以上のプロセッサが提示するステップ、
をさらに含むことを特徴とする請求項1に記載の方法。 - 2mg/dL/分≦[前記検体レベルの前記変化率]であれば、前記修正勧告インスリン投与量が前記勧告インスリン投与量の少なくとも20%の増加を含むことを特徴とする請求項1または2に記載の方法。
- 1mg/dL/分≦[前記検体レベルの前記変化率]<2mg/dL/分であると決定されれば、前記修正勧告インスリン投与量が勧告インスリン投与量の少なくとも10%の増加を含むことを特徴とする請求項1または2に記載の方法。
- −1mg/dL/分≦[前記検体レベルの前記変化率]<1mg/dL/分であると決定されれば、または前記検体レベル変化率が決定され得なければ、前記修正勧告インスリン投与量が無修正の前記勧告インスリン投与量を含むことを特徴とする請求項1または2に記載の方法。
- −2mg/dL/分≦[前記検体レベルの前記変化率]<−1mg/dL/分であると決定されれば、前記修正勧告インスリン投与量が前記勧告インスリン投与量の少なくとも10%の減少を含むことを特徴とする請求項1または2に記載の方法。
- [前記検体レベルの前記決定された変化率]≧−2mg/dL/分であれば、前記修正勧告インスリン投与量が、前記勧告インスリン投与量の少なくとも20%の減少を含むことを特徴とする請求項1または2に記載の方法。
- 前記決定された変化率及び以前の変化率の少なくとも一方を用いて所定の将来時点に対する検体レベル変移を、前記1つ以上のプロセッサが決定するステップ、
前記所定の将来時点に対する前記決定された検体レベル変移に基づいて前記勧告インスリン投与量を、前記1つ以上のプロセッサが修正するステップ、及び
前記ユーザに前記修正勧告インスリン投与量を、前記1つ以上のプロセッサが提示するステップ、
をさらに含むことを特徴とする請求項1から7のいずれか1項に記載の方法。 - 前記受け取られた検体データ、前記決定された変化率、ユーザのインスリン感受性及び検体レベル目標値の内の少なくとも1つを用いて所定の将来時点に対する検体レベル変移を、前記1つ以上のプロセッサが決定するステップ、
前記所定の将来時点に対する前記決定された検体レベル変移に基づいて前記勧告インスリン投与量を、前記1つ以上のプロセッサが修正するステップ、及び
前記ユーザに前記修正勧告インスリン投与量を、前記1つ以上のプロセッサが提示するステップ、
をさらに含むことを特徴とする請求項1から7のいずれか1項に記載の方法。 - 薬物投与デバイスに前記修正勧告インスリン投与量を、前記1つ以上のプロセッサから、前記1つ以上のプロセッサが送信するステップ、
をさらに含むことを特徴とする請求項1から9のいずれか1項に記載の方法。 - 前記時間差が検体センサにともなう較正係数に基づいて決定されることを特徴とする請求項1から10のいずれか1項に記載の方法。
- 傾向感度に基づいて前記勧告インスリン投与量を前記1つ以上のプロセッサが修正するステップをさらに含むことを特徴とする請求項1から11のいずれか1項に記載の方法。
- 受信器ユニット装置において、
ユーザインターフェース、
1つ以上のプロセッサ、及び
前記1つ以上のプロセッサによって実行されると、生体内検体センサからのユーザの検体レベルに関する検体データの受取り、前記受け取られた検体データからの前記ユーザの検体レベルの決定、前記受け取られた検体データ及び以前の検体データを用いる前記ユーザの前記検体レベルの変化率の決定、前記検体レベルの前記決定された変化率に対応する少なくとも1つのビンへの前記ユーザの前記検体レベルに関する前記検体データの分別、前記ユーザの前記決定された検体レベルに基づく、ボーラスである勧告インスリン投与量の決定、前記少なくとも1つのビンへの前記検体データの前記分別に基づく前記勧告インスリン投与量の修正、並びに、間質液中検体レベルと血中検体レベルの間の時間差に基づく前記勧告インスリン投与量の修正、を前記1つ以上のプロセッサに行わせる、命令を格納しているメモリ、
を備えることを特徴とする装置。 - 前記メモリが、前記1つ以上のプロセッサによって実行されると、前記勧告インスリン投与量及び前記修正勧告インスリン投与量の一方または両方の前記ユーザインテーフェース上の提示を前記1つ以上のプロセッサに行わせる、命令を格納していることを特徴とする請求項13に記載の装置。
- 前記メモリが、前記1つ以上のプロセッサによって実行されると、前記決定された変化率及び以前の変化率の少なくとも一方を用いる所定の将来時点に対する検体レベル変移の決定、前記所定の将来時点に対する前記決定された検体レベル変移に基づく前記勧告インスリン投与量の修正、及び前記修正勧告インスリン投与量の前記ユーザインターフェース上の提示、を前記1つ以上のプロセッサに行わせる、命令を格納していることを特徴とする請求項13または14のいずれか1項に記載の装置。
- 前記メモリが、前記1つ以上のプロセッサによって実行されると、前記受け取られた検体データ、前記決定された変化率、ユーザのインスリン感受性及び検体レベル目標値の内の少なくとも1つを用いる所定の将来時点に対する検体レベル変移の決定、前記所定の将来時点に対する前記決定された検体レベル変移に基づく前記勧告インスリン投与量の修正、及び前記ユーザインターフェース上の前記修正勧告インスリン投与量の提示、を前記1つ以上のプロセッサに行わせる、命令を格納していることを特徴とする請求項13または14に記載の装置。
- 前記メモリが、前記1つ以上のプロセッサによって実行されると、検体センサにともなう較正係数に基づく前記時間差の決定を前記1つ以上のプロセッサに行わせる、命令を格納していることを特徴とする請求項13から16のいずれか1項に記載の装置。
- 前記メモリが、前記1つ以上のプロセッサによって実行されると、傾向感度に基づく前記勧告インスリン投与量の修正を前記1つ以上のプロセッサに行わせる、命令を格納していることを特徴とする請求項13から17のいずれか1項に記載の装置。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161582209P | 2011-12-30 | 2011-12-30 | |
US61/582,209 | 2011-12-30 | ||
PCT/US2012/072213 WO2013102158A1 (en) | 2011-12-30 | 2012-12-29 | Method and apparatus for determining medication dose information |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015505264A JP2015505264A (ja) | 2015-02-19 |
JP2015505264A5 JP2015505264A5 (ja) | 2016-02-25 |
JP6479475B2 true JP6479475B2 (ja) | 2019-03-06 |
Family
ID=48698675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014550529A Active JP6479475B2 (ja) | 2011-12-30 | 2012-12-29 | 薬剤投与量情報を決定するための方法及び装置 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20130184547A1 (ja) |
EP (3) | EP3662965B1 (ja) |
JP (1) | JP6479475B2 (ja) |
AU (5) | AU2012362155A1 (ja) |
CA (1) | CA2840644A1 (ja) |
DK (1) | DK3662965T3 (ja) |
FI (1) | FI3662965T3 (ja) |
LT (1) | LT3662965T (ja) |
WO (1) | WO2013102158A1 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
US7697967B2 (en) | 2005-12-28 | 2010-04-13 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US11298058B2 (en) | 2005-12-28 | 2022-04-12 | Abbott Diabetes Care Inc. | Method and apparatus for providing analyte sensor insertion |
US8140312B2 (en) | 2007-05-14 | 2012-03-20 | Abbott Diabetes Care Inc. | Method and system for determining analyte levels |
US9675290B2 (en) | 2012-10-30 | 2017-06-13 | Abbott Diabetes Care Inc. | Sensitivity calibration of in vivo sensors used to measure analyte concentration |
CN102772212A (zh) | 2006-10-26 | 2012-11-14 | 雅培糖尿病护理公司 | 检测被分析物传感器中的信号衰减的方法、设备和系统 |
EP2146625B1 (en) | 2007-04-14 | 2019-08-14 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in medical communication system |
US8591410B2 (en) | 2008-05-30 | 2013-11-26 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8103456B2 (en) | 2009-01-29 | 2012-01-24 | Abbott Diabetes Care Inc. | Method and device for early signal attenuation detection using blood glucose measurements |
US10092229B2 (en) | 2010-06-29 | 2018-10-09 | Abbott Diabetes Care Inc. | Calibration of analyte measurement system |
US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
EP4324399A3 (en) | 2011-04-15 | 2024-05-15 | DexCom, Inc. | Advanced analyte sensor calibration and error detection |
WO2013066849A1 (en) | 2011-10-31 | 2013-05-10 | Abbott Diabetes Care Inc. | Model based variable risk false glucose threshold alarm prevention mechanism |
US8710993B2 (en) | 2011-11-23 | 2014-04-29 | Abbott Diabetes Care Inc. | Mitigating single point failure of devices in an analyte monitoring system and methods thereof |
US10132793B2 (en) | 2012-08-30 | 2018-11-20 | Abbott Diabetes Care Inc. | Dropout detection in continuous analyte monitoring data during data excursions |
EP2901153A4 (en) | 2012-09-26 | 2016-04-27 | Abbott Diabetes Care Inc | METHOD AND DEVICE FOR IMPROVING DELAY CORRECTION FUNCTION DURING IN VIVO MEASUREMENT OF ANALYZ CONCENTRATION WITH ANALYZ CONCENTRATION VARIABILITY AND RANGE DATA |
WO2014152034A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Diabetes Care Inc. | Sensor fault detection using analyte sensor data pattern comparison |
US10433773B1 (en) | 2013-03-15 | 2019-10-08 | Abbott Diabetes Care Inc. | Noise rejection methods and apparatus for sparsely sampled analyte sensor data |
US9474475B1 (en) | 2013-03-15 | 2016-10-25 | Abbott Diabetes Care Inc. | Multi-rate analyte sensor data collection with sample rate configurable signal processing |
EP3089666B1 (en) | 2013-12-31 | 2020-08-19 | Abbott Diabetes Care Inc. | Self-powered analyte sensor and devices using the same |
EP3125761B1 (en) | 2014-03-30 | 2020-09-30 | Abbott Diabetes Care Inc. | Method and apparatus for determining meal start and peak events in analyte monitoring systems |
US9459089B2 (en) * | 2014-04-09 | 2016-10-04 | Qualcomm Incorporated | Method, devices and systems for detecting an attachment of an electronic patch |
CN105517491A (zh) * | 2014-10-22 | 2016-04-20 | 深圳市光聚通讯技术开发有限公司 | 动态血糖监测系统及监测终端 |
US11553883B2 (en) | 2015-07-10 | 2023-01-17 | Abbott Diabetes Care Inc. | System, device and method of dynamic glucose profile response to physiological parameters |
CN105193426B (zh) * | 2015-11-05 | 2016-08-17 | 山东大数据医疗科技有限公司 | 无创式血糖仪 |
CN105496373A (zh) * | 2016-01-02 | 2016-04-20 | 无锡桑尼安科技有限公司 | 智能化医疗辅助系统 |
EP3519011A4 (en) | 2016-09-27 | 2020-05-20 | Bigfoot Biomedical, Inc. | SYSTEMS, DEVICES AND METHODS FOR MEDICATION INJECTION AND DISEASE MANAGEMENT |
EP3500161A4 (en) | 2016-12-12 | 2020-01-08 | Bigfoot Biomedical, Inc. | ALARMS AND WARNINGS FOR MEDICINE DELIVERY DEVICES AND RELATED SYSTEMS AND METHODS |
EP3558117A1 (en) | 2016-12-20 | 2019-10-30 | Abbott Diabetes Care Inc. | Systems, devices and methods for wireless communications in analyte monitoring devices |
US11596330B2 (en) | 2017-03-21 | 2023-03-07 | Abbott Diabetes Care Inc. | Methods, devices and system for providing diabetic condition diagnosis and therapy |
US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
CN212438615U (zh) | 2017-10-24 | 2021-02-02 | 德克斯康公司 | 可穿戴设备 |
CA3084613A1 (en) | 2017-12-12 | 2019-06-20 | Bigfoot Biomedical, Inc. | Therapy assist information and/or tracking device and related methods and systems |
US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
US11197964B2 (en) | 2017-12-12 | 2021-12-14 | Bigfoot Biomedical, Inc. | Pen cap for medication injection pen having temperature sensor |
US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
US11116899B2 (en) * | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
US11083852B2 (en) * | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
USD911355S1 (en) | 2018-03-29 | 2021-02-23 | Bigfoot Biomedical, Inc. | Display screen or portion thereof with graphical user interface |
USD928199S1 (en) | 2018-04-02 | 2021-08-17 | Bigfoot Biomedical, Inc. | Medication delivery device with icons |
AU2020205079A1 (en) * | 2019-01-04 | 2021-06-24 | Abbott Diabetes Care Inc. | Systems, devices, and methods for improved meal and therapy interfaces in analyte monitoring systems |
US10998091B2 (en) * | 2019-02-07 | 2021-05-04 | Sandeep Patil | Systems for monitoring compliance with a patch dosage regimen and methods of using the same |
WO2020172628A1 (en) * | 2019-02-21 | 2020-08-27 | Companion Medical, Inc. | Methods, systems and devices for a medicament dose calculator |
US11776684B2 (en) | 2019-09-26 | 2023-10-03 | Pacesetter, Inc | Method and device for managing energy usage by a medical device |
AU2020381452A1 (en) * | 2019-11-15 | 2022-05-26 | Dexcom, Inc. | Joint state estimation prediction that evaluates differences in predicted vs. corresponding received data |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264104A (en) | 1989-08-02 | 1993-11-23 | Gregg Brian A | Enzyme electrodes |
US5262035A (en) | 1989-08-02 | 1993-11-16 | E. Heller And Company | Enzyme electrodes |
US5593852A (en) | 1993-12-02 | 1997-01-14 | Heller; Adam | Subcutaneous glucose electrode |
US5262305A (en) | 1991-03-04 | 1993-11-16 | E. Heller & Company | Interferant eliminating biosensors |
US5320715A (en) | 1994-01-14 | 1994-06-14 | Lloyd Berg | Separation of 1-pentanol from cyclopentanol by extractive distillation |
DE29711371U1 (de) | 1997-06-30 | 1997-11-27 | Siemens AG, 80333 München | Vorrichtung zur Verbindung von Leiterplatten getrennter Geräte |
US8974386B2 (en) * | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
US6036508A (en) | 1998-12-21 | 2000-03-14 | Hamilton Sundstrand Corporation | Connector for interconnecting a bus bar to a circuit board |
US7806886B2 (en) * | 1999-06-03 | 2010-10-05 | Medtronic Minimed, Inc. | Apparatus and method for controlling insulin infusion with state variable feedback |
WO2001088524A1 (en) | 2000-05-12 | 2001-11-22 | Therasense, Inc. | Electrodes with multilayer membranes and methods of using and making the electrodes |
US6882940B2 (en) * | 2000-08-18 | 2005-04-19 | Cygnus, Inc. | Methods and devices for prediction of hypoglycemic events |
US20030208113A1 (en) * | 2001-07-18 | 2003-11-06 | Mault James R | Closed loop glycemic index system |
US6544212B2 (en) * | 2001-07-31 | 2003-04-08 | Roche Diagnostics Corporation | Diabetes management system |
JP2003084101A (ja) | 2001-09-17 | 2003-03-19 | Dainippon Printing Co Ltd | 光学素子用樹脂組成物、光学素子、およびプロジェクションスクリーン |
US8010174B2 (en) * | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
US7299082B2 (en) | 2003-10-31 | 2007-11-20 | Abbott Diabetes Care, Inc. | Method of calibrating an analyte-measurement device, and associated methods, devices and systems |
WO2005057175A2 (en) * | 2003-12-09 | 2005-06-23 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
WO2009048462A1 (en) * | 2007-10-09 | 2009-04-16 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US7291107B2 (en) * | 2004-08-26 | 2007-11-06 | Roche Diagnostics Operations, Inc. | Insulin bolus recommendation system |
US7869851B2 (en) * | 2004-12-23 | 2011-01-11 | Roche Diagnostics Operations, Inc. | System and method for determining insulin bolus quantities |
US7547281B2 (en) * | 2005-02-01 | 2009-06-16 | Medtronic Minimed, Inc. | Algorithm sensor augmented bolus estimator for semi-closed loop infusion system |
KR100638727B1 (ko) | 2005-02-28 | 2006-10-30 | 삼성전기주식회사 | Zigbee 및 불루투스 겸용 송수신기 |
US8473022B2 (en) * | 2008-01-31 | 2013-06-25 | Abbott Diabetes Care Inc. | Analyte sensor with time lag compensation |
US7630748B2 (en) | 2006-10-25 | 2009-12-08 | Abbott Diabetes Care Inc. | Method and system for providing analyte monitoring |
US7946985B2 (en) * | 2006-12-29 | 2011-05-24 | Medtronic Minimed, Inc. | Method and system for providing sensor redundancy |
US20080228056A1 (en) | 2007-03-13 | 2008-09-18 | Michael Blomquist | Basal rate testing using frequent blood glucose input |
EP2156346A1 (en) * | 2007-05-03 | 2010-02-24 | Novo Nordisk A/S | Safety system for insulin delivery advisory algoritms |
US10002233B2 (en) * | 2007-05-14 | 2018-06-19 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
US8417311B2 (en) * | 2008-09-12 | 2013-04-09 | Optiscan Biomedical Corporation | Fluid component analysis system and method for glucose monitoring and control |
US7751907B2 (en) * | 2007-05-24 | 2010-07-06 | Smiths Medical Asd, Inc. | Expert system for insulin pump therapy |
US8444595B2 (en) * | 2007-06-15 | 2013-05-21 | Animas Corporation | Methods to pair a medical device and at least a remote controller for such medical device |
US20090143725A1 (en) * | 2007-08-31 | 2009-06-04 | Abbott Diabetes Care, Inc. | Method of Optimizing Efficacy of Therapeutic Agent |
US8377031B2 (en) * | 2007-10-23 | 2013-02-19 | Abbott Diabetes Care Inc. | Closed loop control system with safety parameters and methods |
US20090240127A1 (en) * | 2008-03-20 | 2009-09-24 | Lifescan, Inc. | Methods of determining pre or post meal time slots or intervals in diabetes management |
US8924159B2 (en) * | 2008-05-30 | 2014-12-30 | Abbott Diabetes Care Inc. | Method and apparatus for providing glycemic control |
US8734422B2 (en) * | 2008-08-31 | 2014-05-27 | Abbott Diabetes Care Inc. | Closed loop control with improved alarm functions |
US9402544B2 (en) | 2009-02-03 | 2016-08-02 | Abbott Diabetes Care Inc. | Analyte sensor and apparatus for insertion of the sensor |
WO2010135686A2 (en) * | 2009-05-22 | 2010-11-25 | Abbott Diabetes Care Inc. | Adaptive insulin delivery system |
US8579879B2 (en) * | 2010-02-19 | 2013-11-12 | Medtronic Minimed, Inc. | Closed-loop glucose control startup |
-
2012
- 2012-12-29 CA CA2840644A patent/CA2840644A1/en active Pending
- 2012-12-29 US US13/730,970 patent/US20130184547A1/en not_active Abandoned
- 2012-12-29 AU AU2012362155A patent/AU2012362155A1/en not_active Abandoned
- 2012-12-29 WO PCT/US2012/072213 patent/WO2013102158A1/en active Application Filing
- 2012-12-29 LT LTEP19200742.5T patent/LT3662965T/lt unknown
- 2012-12-29 DK DK19200742.5T patent/DK3662965T3/da active
- 2012-12-29 JP JP2014550529A patent/JP6479475B2/ja active Active
- 2012-12-29 FI FIEP19200742.5T patent/FI3662965T3/fi active
- 2012-12-29 EP EP19200742.5A patent/EP3662965B1/en active Active
- 2012-12-29 EP EP12863276.7A patent/EP2797660B1/en active Active
- 2012-12-29 EP EP23191714.7A patent/EP4249034A3/en active Pending
-
2017
- 2017-09-14 AU AU2017228654A patent/AU2017228654A1/en not_active Abandoned
-
2019
- 2019-02-15 US US16/277,137 patent/US20190192071A1/en active Pending
- 2019-03-01 AU AU2019201453A patent/AU2019201453B2/en active Active
-
2021
- 2021-11-11 AU AU2021266271A patent/AU2021266271B2/en active Active
-
2024
- 2024-04-11 AU AU2024202384A patent/AU2024202384A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2840644A1 (en) | 2013-07-04 |
EP2797660B1 (en) | 2019-10-02 |
FI3662965T3 (fi) | 2024-07-10 |
US20190192071A1 (en) | 2019-06-27 |
AU2012362155A1 (en) | 2014-01-23 |
AU2024202384A1 (en) | 2024-05-02 |
AU2019201453A1 (en) | 2019-03-21 |
LT3662965T (lt) | 2024-08-12 |
EP4249034A3 (en) | 2023-11-15 |
WO2013102158A1 (en) | 2013-07-04 |
EP2797660A1 (en) | 2014-11-05 |
AU2017228654A1 (en) | 2017-10-05 |
JP2015505264A (ja) | 2015-02-19 |
AU2021266271A1 (en) | 2021-12-09 |
DK3662965T3 (da) | 2024-07-22 |
EP3662965A1 (en) | 2020-06-10 |
EP3662965B1 (en) | 2024-05-01 |
AU2019201453B2 (en) | 2021-08-12 |
AU2021266271B2 (en) | 2024-01-11 |
US20130184547A1 (en) | 2013-07-18 |
EP4249034A2 (en) | 2023-09-27 |
EP2797660A4 (en) | 2015-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6479475B2 (ja) | 薬剤投与量情報を決定するための方法及び装置 | |
US20210196156A1 (en) | Mitigating Single Point Failure of Devices in an Analyte Monitoring System and Methods Thereof | |
US20240038381A1 (en) | Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof | |
US9339219B2 (en) | Devices, systems, and methods related to analyte monitoring and management | |
US12059272B2 (en) | Method and device for analyzing continuously monitored physiological measurement values of a user | |
US20140060145A1 (en) | Analyte Monitoring Methods, Devices and Systems for Recommending Confirmation Tests | |
CN113261065A (zh) | 用于改进分析物监测系统中膳食和治疗接口的系统、装置和方法 | |
CN109074868A (zh) | 利用概率葡萄糖测量结果的丸剂计算器 | |
WO2014036175A1 (en) | Modifying a sensitivity value to adjust for lag between in vivo sensor analyte values and an in vitro reference analyte value |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151228 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151228 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160916 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170214 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170808 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171108 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180717 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181017 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190206 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6479475 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |